Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
Crossref DOI link: https://doi.org/10.1007/s13300-021-01182-z
Published Online: 2021-12-06
Published Print: 2022-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Li, Qifu
Zhang, Qiqi
Wang, Rui
Hong, Tianpei http://orcid.org/0000-0002-5744-5129
Funding for this research was provided by:
Eli Lilly and Company
Text and Data Mining valid from 2021-12-06
Version of Record valid from 2021-12-06
Article History
Received: 7 September 2021
Accepted: 15 November 2021
First Online: 6 December 2021